non semaglutide weight loss drugs for in non-diabetics Experts warn about risks of

Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year September 10, 2025 According to a new data update from REGENXBIO's pivotal phase 1/2/3 CAMPSIITE clinical trial (NCT03566043) evaluating clemidsogene lanparvovec (RGX-121), an investigational adeno-associated virus (AAV) vector-based gene therapy for mucopolysaccharidosis type 2 (MPSII, also known as Hunter syndrome), 13 patients treated in the pivotal phase have shown an 82% reduction in heparan sulfate (HS) D2S6 levels in the cerebrospinal fluid (CSF) through 1 year posttreatment

So, give this a try the next time you but grapefruit

The ASCT2/SLC1A5 and SNAT1/SLC38A1 genes were expressed at moderate levels, while the genes of ASCT1/SLC1A4 and SNAT5/SLC38A5 were at low levels in brain endothelial cells

1 mg dose pen: Pen delivers a 1 mg dose